Search Result

Results for "

T-type

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Apoptosis (1) Calcium Channel (79) Caspase (1) Cytochrome P450 (2) Dopamine Receptor (5) Drug Isomer (1) Endogenous Metabolite (6) Environmental Pollutants (1) Isotope-Labeled Compounds (8) Potassium Channel (1) Reference Standards (13) SARS-CoV (4) Sodium Channel (9)
By Research Areas:	Cancer (15) Cardiovascular Disease (17) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (4) Neurological Disease (63)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15553A

Mibefradil dihydrochloride Maximum Cited Publications 14 Publications Verification Ro 40-5967 dihydrochloride	Calcium Channel	Cardiovascular Disease Cancer
Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca ²⁺ channels (IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively) .

HY-B1378

Ethosuximide 1 Publications Verification	Calcium Channel	Neurological Disease Cancer
Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.

HY-50722

NNC 55-0396 5 Publications Verification NNC 55-0396 dihydrochloride	Calcium Channel Cytochrome P450	Cardiovascular Disease Neurological Disease Cancer
NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable T-type Ca ²⁺ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca ²⁺ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma .

HY-10035

TTA-P2 2 Publications Verification T-type calcium channel inhibitor	Calcium Channel	Neurological Disease
TTA-P2 (T-Type calcium channel inhibitor) is a selective, orally active, and BBB-penetrant T-type calcium channel blocker (IC₅₀ = 22 nM). TTA-P2 reduces mechanical hypersensitivity and alleviates acute as well as chronic pain. TTA-P2 significantly reduces firing rates in temporal lobe epilepsy (TLE) neurons to control levels and suppresses synaptically evoked burst firing. TTA-P2 can be studied in research for neurological diseases such as tremor and absence epilepsy < sup>[4] .

HY-111828

TTA-A2 1 Publications Verification	Calcium Channel	Neurological Disease
TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a₁G) and Cav3.2 (a₁H) channels with IC₅₀ values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .

HY-B0358

Flunarizine 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D₂ dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-112723

Apinocaltamide ACT-709478	Calcium Channel	Neurological Disease
Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies .

HY-B0358A

Flunarizine dihydrochloride 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-W032013

1-Octanol 1 Publications Verification Octanol	Environmental Pollutants Endogenous Metabolite Calcium Channel	Neurological Disease Metabolic Disease
1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-120546

Ulixacaltamide 1 Publications Verification Z944; PRAX-944	Calcium Channel	Neurological Disease Inflammation/Immunology
Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .

HY-A0092

Trimethadione 3,5,5,-Trimethyloxazolidine-2,4-dione	Calcium Channel	Neurological Disease
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .

HY-12502A

Efonidipine hydrochloride monoethanolate 1 Publications Verification NZ-105 hydrochloride monoethanolate; (±)-Efonidipine hydrochloride monoethanolate	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-B0768A

Lomerizine dihydrochloride 1 Publications Verification KB-2796	Calcium Channel	Neurological Disease
Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.

HY-103309

ML218 2 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-101096

Suvecaltamide MK-8998; CX-8998; JZP385	Calcium Channel	Neurological Disease Cancer
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .

HY-132184

5,6-Epoxyeicosatrienoic acid 5,6-EET; (±)5,6-EpETrE	Adrenergic Receptor Calcium Channel	Endocrinology
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.

HY-15553

Mibefradil Ro 40-5967	Calcium Channel	Cardiovascular Disease Cancer
Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca ²⁺ channels displaying IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively .

HY-120597

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated Ca ²⁺ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca ²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .

HY-12502

Efonidipine 1 Publications Verification NZ-105; (±)-Efonidipine	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-19721

ABT-639 3 Publications Verification	Calcium Channel	Neurological Disease
ABT-639 is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

HY-136909

SR33805	Calcium Channel	Cardiovascular Disease
SR33805 is a potent Ca ²⁺ channel antagonist, with EC₅₀s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca ²⁺ channels. SR33805 can be used for the research of acute or chronic failing hearts .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective *P/Q type* Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀** of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-147638

MONIRO-1	Calcium Channel	Neurological Disease
MONIRO-1 is a T-type and N-type calcium channel blocker with IC₅₀ values of 34, 3.3, 1.7 and 7.2 µM against hCa_v2.2, hCa_v3.1, hCa_v3.2 and hCa_v3.3, respectively. MONIRO-1 has low activity against L-type calcium channels. MONIRO-1 can be used for the study of pain and epilepsy .

HY-115681

(2R/S)-6-PNG 1 Publications Verification 6-Prenylnaringenin; (±)-6-Prenylnaringenin	Calcium Channel	Neurological Disease
(2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible *Ca_v3.2 T-type* Ca ²⁺ channels (T-channels)** blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .

HY-50707

(Rac)-TTA-P2 (Rac)-T-type calcium channel inhibitor	Calcium Channel Drug Isomer	Neurological Disease
(Rac)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-10388A

TTA-Q6(isomer)	Calcium Channel	Others
TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective T-type Ca ²⁺ channel antagonist.

HY-Z8176

(Z)-Flunarizine	Sodium Channel	Neurological Disease
(Z)-Flunarizine is the (Z)-isomer of Flunarizine (HY-B0358). Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-B0358AR

Flunarizine dihydrochloride (Standard)	Reference Standards Calcium Channel Sodium Channel Dopamine Receptor	Neurological Disease
Flunarizine (dihydrochloride) (Standard) is the analytical standard of Flunarizine (dihydrochloride). This product is intended for research and analytical applications. Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-W032013S1

1-Octanol-d2 Octanol-d₂	Calcium Channel Endogenous Metabolite	Metabolic Disease
1-Octanol-d₂ is the deuterium labeled 1-Octanol . 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-147708

T-Type calcium channel inhibitor 2	Calcium Channel	Cancer
T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC₅₀s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC₅₀s of 5.0, 6.4 µM, respectively .

HY-150541

IAA65	Calcium Channel	Neurological Disease
IAA65 is a potent T-type calcium channel inhibitor with a IC₅₀ value of 18.9 µM. IAA65 can be used for epilepsy research .

HY-151452

Cav 3.2 inhibitor 3	Calcium Channel	Neurological Disease
Cav 3.2 inhibitor 3 (Compound 4) is a potent *Ca_v3.2 T-type* Ca ²⁺ channel inhibitor with an IC₅₀** of 0.1534 μM, and has little binding affinity to D₂ receptors .

HY-126336

HM12	Calcium Channel	Cardiovascular Disease Neurological Disease
HM12 is a covalent inhibitor of *L-/T-type* calcium channels. HM12 can strongly inhibit the Cav1.2** (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc .

HY-10035R

TTA-P2 (Standard) T-type calcium channel inhibitor (Standard)	Calcium Channel Reference Standards	Neurological Disease
TTA-P2 (Standard) is the analytical standard of TTA-P2 (HY-10035). This product is intended for research and analytical applications. TTA-P2 (T-Type calcium channel inhibitor) is a selective, orally active, and BBB-penetrant T-type calcium channel blocker (IC50 = 22 nM). TTA-P2 reduces mechanical hypersensitivity and alleviates acute as well as chronic pain. TTA-P2 significantly reduces firing rates in temporal lobe epilepsy (TLE) neurons to control levels and suppresses synaptically evoked burst firing. TTA-P2 can be studied in research for neurological diseases such as tremor and absence epilepsy < sup> .

HY-B0358AS

Flunarizine-d8 dihydrochloride	Sodium Channel Dopamine Receptor Calcium Channel Isotope-Labeled Compounds	Neurological Disease
Flunarizine-d₈ dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-12502B

Efonidipine hydrochloride NZ-105 hydrochloride; (±)-Efonidipine hydrochloride	Calcium Channel SARS-CoV	Cardiovascular Disease Cancer
Efonidipine (NZ-105) hydrochloride is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-W032013R

1-Octanol (Standard) Octanol (Standard)	Reference Standards Calcium Channel Endogenous Metabolite	Neurological Disease Metabolic Disease
1-Octanol (Standard) is the analytical standard of 1-Octanol. This product is intended for research and analytical applications. 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-120484

A-1048400	Calcium Channel	Neurological Disease
A-1048400 is an orally active and selective calcium channel inhibitor with an IC₅₀ value of 1.4 μM for N-type channels, 1.2 μM for T-type channel. A-1048400 inhibits neurotransmitter release and reduces membrane hyperexcitability, exerting potent analgesic activity. A-1048400 is promising for research of neuropathic pain (e.g., pain induced by spinal nerve ligation and chronic constriction injury) .

HY-150539

IAB15	Calcium Channel	Neurological Disease
IAB15 is a potent T-type calcium channel inhibitor. IAB15 can be used for epilepsy research .

HY-10035A

(R)-TTA-P2	Calcium Channel	Neurological Disease
(R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-P5869

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca ²⁺ channel gating inhibitor with a K_d of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

HY-10955

TTA-P1	Calcium Channel	Neurological Disease
TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy .

HY-154832

Cav 3.2 inhibitor 4	Calcium Channel	Cardiovascular Disease
Cav 3.2 inhibitor 4 (compound 21) is a potent, peripherally restricted, selective T-type calcium channel (Ca_v3.2) inhibitor, with an IC₅₀ of 0.6 μM. Cav 3.2 inhibitor 4 can be used for the research of atrial fibrillation .

HY-151450

Cav 3.2 inhibitor 1	Calcium Channel	Neurological Disease Inflammation/Immunology
Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain .

HY-14232

TTA-A8	Calcium Channel	Neurological Disease
TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC₅₀ value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .

HY-A0092R

Trimethadione (Standard) 3,5,5,-Trimethyloxazolidine-2,4-dione (Standard)	Reference Standards Calcium Channel	Neurological Disease
Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .

HY-B0768

Lomerizine KB-2796 free base	Calcium Channel	Neurological Disease
Lomerizine is an antagonist of L- and T-type voltagegated calcium channels.

HY-101616

ABT-639 hydrochloride	Calcium Channel	Neurological Disease
ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

HY-B0768AR

Lomerizine dihydrochloride (Standard) KB-2796 (Standard)	Reference Standards Calcium Channel	Neurological Disease
Lomerizine dihydrochloride (Standard) is the analytical standard of Lomerizine dihydrochloride. This product is intended for research and analytical applications. Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.

HY-10388

TTA-Q6 1 Publications Verification	Calcium Channel	Neurological Disease
TTA-Q6 is a selective T-type Ca ²⁺ channel antagonist, which can be used in the research of neurological disease .

Cat. No.	Product Name	Target	Research Area

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective *P/Q type* Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀** of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-P5869

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca ²⁺ channel gating inhibitor with a K_d of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian *N-type* calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian *N-type* calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W032013

1-Octanol 1 Publications Verification Octanol	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Environmental Pollutants Endogenous Metabolite Calcium Channel
1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-W032013R

1-Octanol (Standard) Octanol (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Calcium Channel Endogenous Metabolite
1-Octanol (Standard) is the analytical standard of 1-Octanol. This product is intended for research and analytical applications. 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

Cat. No.	Product Name	Chemical Structure

HY-W032013S1

1-Octanol-d2
1-Octanol-d₂ is the deuterium labeled 1-Octanol . 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-B0358AS

Flunarizine-d8 dihydrochloride
Flunarizine-d₈ dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-B0768S

Lomerizine-d4
Lomerizine-d4 is the deuterium labeled Lomerizine (HY-B0768). Lomerizine is an antagonist of L- and T-type voltagegated calcium channels .

HY-B1378S1

Ethosuximide-d5
Ethosuximide-d₅ is deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.

HY-B1378S

Ethosuximide-d3
Ethosuximide-d₃ is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel .

HY-W032013S

1-Octanol-d17
1-Octanol-d₁₇ is the deuterium labeled 1-Octanol . 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC₅₀ of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-W032013S3

1-Octanol-d5
1-Octanol-d₅ is deuterated labeled 1-Octanol (HY-W032013). 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-W032013S2

1-Octanol-d2-1
1-Octanol-d₂-1 is deuterated labeled 1-Octanol (HY-W032013). 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .

HY-103309S

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11

5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid is one of the four major epoxyeicosatrienoic acid (EET) isomers metabolized from Arachidonic acid (HY-109590). 5,6-Epoxyeicosatrienoic acid induces peripheral vasodilation and lowers blood pressure by inhibiting T-type calcium channels (Cav3.2: IC₅₀ = 0.54 μM). 5,6-Epoxyeicosatrienoic acid causes vasoconstriction in hypoxic pulmonary blood vessels via activating Rho kinase in a membrane depolarization-dependent manner. 5,6-Epoxyeicosatrienoic acid induces mechanical pain by activating TRPA1. 5,6-Epoxyeicosatrienoic acid can be used in studies related to hypoxic pulmonary vasoconstriction, mechanical hyperalgesia and hypertension.

HY-B1378S2

Ethosuximide-13C, d3
Ethosuximide- ¹³C, d₃ is the ¹³C- and deuterium labeled Ethosuximide (HY-B1378). Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82974

	Cardiac Troponin T Antibody (YA2719) TNNT2; Cardiac muscle troponin T; Troponin T; cardiac muscle; troponin T type 2 (cardiac); Cardiac muscle troponin T antibody Cardiomyopathy dilated 1D (autosomal dominant) antibody; Cardiomyopathy hypertrophic 2 antibody; CMD1D antibody; CMH2 antibody; CMPD2 antibody; cTnT antibody; LVNC6 antibody; MGC3889 antibody; OTTHUMP00000033864 antibody; RCM3 antibody; TNNT 2 antibody; TNNT2 antibody; TNNT2_HUMAN antibody; TnTc antibody; Troponin T cardiac muscle antibody; Troponin T2 cardiac antibody	WB, IHC-P, IF-Tissue	Human, Mouse, Rat
	Cardiac Troponin T Antibody (YA2719) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cardiac Troponin T.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks